Baricitinib treatment linked to reduced mortality in COVID-19 patients

(Karolinska Institutet) The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news